Skip to content

Evidence-based evaluation study of Beimu Zhizhu granules in the treatment of reflux cough

Evidence-based evaluation study of Beimu Zhizhu granules in the treatment of reflux cough

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000387
Enrollment
Unknown
Registered
2024-09-05
Start date
2024-09-10
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux cough

Interventions

Observation group:The observation group was given Beimu Zhizhu Granules (mainly composed of 10g of bran fried Fructus Aurantii, 12g of bran fried Atractylodes macrocephala, 15g of Poria cocos, 3g of C
Oral administration of omeprazole enteric coated capsule mimetic, 1 capsule per time, once daily, 30 minutes before breakfast. The treatment pe
Control group:The control group was given omeprazole enteric coated capsules orally, 20mg each time, once a day, 30 minutes before breakfast
Beimu Zhizhu Granules Simulated Oral Administration, 1 dose per day, diluted with 50-100ml water, taken 30 minutes after breakfast and dinner. The treatment period is 8 weeks.

Sponsors

Wangjing Hospital China Academy of Chinese Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Individuals who meet the diagnostic criteria for reflux cough in both traditional Chinese and Western medicine; 2) In the past 4 weeks, have not taken with cough, anti-reflux, acid inhibition effect of Chinese medicine/proprietary Chinese medicine/Western medicine; Age =18 years old; 4) Voluntarily accept the treatment plan and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Merge other cough causing diseases; 2) Merge severe primary diseases such as cardiovascular, cerebrovascular, liver and kidney, hematopoietic and endocrine systems, and malignancy Tumor patients and high-risk individuals for fractures; 3) Pregnant and lactating women; 4) Individuals who have participated or are currently participating in other clinical trials within the past month; 5) Taking warfarin, clopidogrel, aspirin, fenavir/azavir/nefenavir/ Shaquinavir, tacrolimus, voriconazole/posaconazole/ketoconazole/itraconazole, erlotinib, ciloconazole Tazole, diazepam, digoxin, methotrexate, phenytoin, nifedipine, rifampicin, St. John's wort and other drugs Objects; 6) Individuals who are known to be allergic to the treatment drugs specified in the protocol.

Design outcomes

Primary

MeasureTime frame
Cough evaluationg test;

Secondary

MeasureTime frame
Color Doppler gastrointestinal contrast ultrasound;Leicester cough questionnair;Salivary bile acid;Salivary pepsin;Reflux Cough Rating Scale;

Countries

China

Contacts

Public ContactWang Bin

Wangjing Hospital of the Chinese Academy of Traditional Chinese Medicine

wjyyhxkwb@163.com13146098570

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026